The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of Type I collagen, new markers of bone resorption

Journal of Endocrinological Investigation

Volumn 21, Issue 3, 1998, Pages 154-159

  Taga, M ^a   Uemura, T ^a   Minaguchi, H ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Bone metabolic marker; Bone resorption; C telopeptide; HRT; N telopeptide

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; DEOXYPYRIDINOLINE; HYDROXYPROLINE; MEDROXYPROGESTERONE ACETATE; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; OSTEOLYSIS; POSTMENOPAUSE; URINARY EXCRETION;

EID: 0031924602     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347294     Document Type: Article

References (14)

1. Kiel D.P., Felson D.T., Andersen J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. N. Engl. J. Med. 317: 1169, 1987.
2. Garnero P., Gineyts E., Riou J.P., Delmas P.D. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79: 780, 1994.
3. Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7: 1251, 1992.
4. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Evaluation of an immunoassay for quantitation of type I collagen degradation products in urine. Clin. Chem. 40: 2022, 1994.
5. Prestwood K.M., Pilbeam C.C., Burleson J.A., Woodiel F.N., Delmas P.D., Deftos L.J., Raisz L.G. The short term effects of conjugated estrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 79: 366, 1994.
6. Uebelhart D., Shelemmer A., Johansen J.S., Gineyts E., Christiansen C., Delmas P.D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinum cross-links. J. Clin. Endocrinol. Metab. 72: 367, 1991.
7. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 10: 641, 1995.
8. Uebelhart D., Gineyts E., Chapuy M.C., Delmas P.D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 8: 87, 1990.
9. Marslew U., Riis B.J., Christiansen C. Bleeding patterns during continuous combined oestrogen-progestogen therapy. Am. J. Obstet. Gynecol. 164: 1163, 1991.
10. Greg A.B., Cundy T.F., Reid I.R. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin. Endocrinol. (Oxf.) 40: 671, 1994.
11. Chistiansen C. Treatment of osteoporosis. In: Lobo R.A. (Ed.) Treatment of the postmenopausal women: Basic and clinical aspects. Raven Press Ltd., New York, 1994.
12. Seyedin E.M., Kung V.T., Daniloff Y.N., Hesley R.P., Gomez B., Nielsen L.A., Rosen H.N., Zuk R.F. Immunoassay for urinary pyridinoline: the new marker for bone resorption. J. Bone Miner. Res. 8: 635, 1993.
13. Risteli J., Elonaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem. 39: 635, 1993.
14. Burgeson R.E. New collagens, new concepts. Annu. Rev. Cell. Biol. 4: 552, 1988.